Following reports of adverse cardiovascular events including fatal heart attack, stroke and advancement of coronary artery disease among patients, the FDA has released a safety communication for the leukemia drug ponatinib. The agency is looking into the issue and has advised clinicians to evaluate the risks and benefits when prescribing the medication.

Related Summaries